期刊首页 优先出版 当期阅读 过刊浏览 作者中心 关于期刊 English

《工程(英文)》 >> 2017年 第3卷 第1期 doi: 10.1016/J.ENG.2017.01.017

肠道菌群与肿瘤发生及肝病

a International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China
b National Center for Liver Cancer, Shanghai 201805, China

录用日期: 2017-02-03 发布日期: 2017-02-28

下一篇 上一篇

摘要

一个多世纪以前,科学家们就首次发现了肿瘤区域中细菌的存在。但是,微生物在肿瘤发生中的作用近年来才被认识到。近几十年来,与肠道菌群失调相关的疾病代表了全世界最严重的一些公共卫生问题。大量的流行病学研究表明,肠道菌群与某些常见肿瘤密切相关。然而,肠道菌群与肿瘤相关联的具体分子机制仍不明确。研究表明,肠道菌群的改变有助于确定肝癌、酒精相关肝病、非酒精性脂肪肝和肝硬化的发生和发展。鉴于益生菌是一种可通过调节免疫系统促进人类健康的药物,其可能会为肝细胞癌(HCC) 和非酒精性脂肪肝的治疗提供新方向。本文总结了肠道菌群在肿瘤及肝病中的研究进展,综述了肠道菌群与肿瘤和肝病之间的关系。此外,考虑到细菌内稳态的重要性,我们也对益生菌进行了概述,旨在为相关疾病的治疗提供指导。

图片

图1

参考文献

[ 1 ] Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et alA human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464(7285):59–65 链接1

[ 2 ] Zoetendal EG, Akkermans AD, De Vos WM. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 1998;64(10):3854–9.

[ 3 ] Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et alDiversity of the human intestinal microbial flora. Science 2005;308(5728):1635–8 链接1

[ 4 ] Hold GL, Pryde SE, Russell VJ, Furrie E, Flint HJ. Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis. FEMS Microbiol Ecol 2002;39(1):33–9 链接1

[ 5 ] Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, Chinwalla AT, et alStructure, function and diversity of the healthy human microbiome. Nature 2012;486(7402):207–14 链接1

[ 6 ] Tamburini S, Shen N, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Nat Med 2016;22(7):713–22 链接1

[ 7 ] Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature 2016;535(7610):65–74 链接1

[ 8 ] Schroeder BO, B?ckhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med 2016;22(10):1079–89 链接1

[ 9 ] Ou J, Carbonero F, Zoetendal EG, DeLany JP, Wang M, Newton K, et alDiet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. Am J Clin Nutr 2013;98(1):111–20 链接1

[10] Uronis JM, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009;4(6):e6026 链接1

[11] Irrazábal T, Belcheva A, Girardin SE, Martin A, Philpott DJ. The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell 2014;54(2):309–20 链接1

[12] Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et alAdenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012;491(7423):254–8 链接1

[13] Couturier-Maillard A, Secher T, Rehman A, Normand S, De Arcangelis A, Haesler R, et alNOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 2013;123(2):700–11 链接1

[14] Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007;449(7164):819–26 链接1

[15] Yu L, Yan H, Liu Q, Yang W, Wu H, Dong W, et alEndotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010;52(4):1322–33 链接1

[16] Zhang H, Yu L, Yang W, Tang L, Lin Y, Wu H, et alProfound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol 2012;57(4):803–12 链接1

[17] Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, et alPromotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21(4):504–16 链接1

[18] Roderburg C, Luedde T. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut Microbes 2014;5(4):441–5 链接1

[19] Tao X, Wang N, Qin W. Gut microbiota and hepatocellular carcinoma. Gastrointest Tumors 2015;2(1):33–40 链接1

[20] B?ckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007;104(3):979–84 链接1

[21] Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444(7122):1027–31 链接1

[22] Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NM, Magness S, et alHigh-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 2010;5(8):e12191 链接1

[23] Fleissner CK, Huebel N, Abd El-Bary MM, Loh G, Klaus S, Blaut M. Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr 2010;104(6):919–29 链接1

[24] Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol 2012;9(10):577–89 链接1

[25] Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et alObesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499(7456):97–101. Erratum in: Nature 2014;506(7488):396 链接1

[26] Ray K. Gut microbiota: obesity-induced microbial metabolite promotes HCC. Nat Rev Gastroenterol Hepatol 2013;10(8):442 链接1

[27] Li J, Sung CY, Lee N, Ni Y, Pihlajamaki J, Panagiotou G, et alProbiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci USA 2016;113(9):E1306–15 链接1

[28] El-Nezami HS, Polychronaki NN, Ma J, Zhu H, Ling W, Salminen EK, et alProbiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China. Am J Clin Nutr 2006;83(5):1199–203.

[29] de Alwis NMW, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008;48(Suppl 1):S104–12 链接1

[30] Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et alSimilarities and differences in outcomes of cirrhosis due to non-alcoholic steatohepatitis and hepatitis C. Hepatology 2006;43(4):682–9 链接1

[31] Nair S, Mason A, Eason J, Loss G, Perillo R. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36(1):150–5 链接1

[32] Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et alInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482(7384):179–85 链接1

[33] Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et alThe economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64(5):1577–86 链接1

[34] Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, et alNLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011;145(5):745–57 链接1

[35] Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, et alLinkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012;302(1):G168–75 链接1

[36] Makiura N, Ojima M, Kou Y, Furuta N, Okahashi N, Shizukuishi S, et alRelationship of Porphyromonas gingivalis with glycemic level in patients with type 2 diabetes following periodontal treatment. Oral Microbiol Immunol 2008;23(4):348–51 链接1

[37] Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota—farnesoid X receptor axis modulates metabolic disease. Gastroenterology 2016;151(5):845–59 链接1

[38] Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, et alIntestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015;21(2):159–65 链接1

[39] Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, et alIntestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015;6:10166 链接1

[40] Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, et alCancer and the gut microbiota: an unexpected link. Sci Transl Med 2015;7(271):271ps1 链接1

[41] Perez-Chanona E, Trinchieri G. The role of microbiota in cancer therapy. Curr Opin Immunol 2016;39:75–81 链接1

[42] Arroyo R, Martin V, Maldonado A, Jimenez E, Fernandez L, Rodriguez JM. Treatment of infectious mastitis during lactation: antibiotics versus oral administration of lactobacilli isolated from breast milk. Clin Infec Dis 2010;50(12):1551–8 链接1

[43] Barbonetti A, Vassallo MR, Cinque B, Filipponi S, Mastromarino P, Cifone MG, et alSoluble products of Escherichia coli induce mitochondrial dysfunction-related sperm membrane lipid peroxidation which is prevented by lactobacilli. PLoS One 2013;8(12):e83136 链接1

[44] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et alCommensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350(6264):1084–9 链接1

[45] Alderton GK. Tumour immunology: intestinal bacteria are in command. Nat Rev Immunol 2016;16(1):5 链接1

相关研究